Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Analysts have a consensus “Hold” rating on Medpace, with nine holds and three buys among 12 brokerages. The average 12-month price target is $595.20, near the stock’s $593.39 opening price.
• Medpace reported stronger-than-expected quarterly results, with EPS of $4.25 versus a $3.98 estimate and revenue of $707.33 million, up 17.2% year over year. Analysts expect full-year 2026 EPS of approximately $17.54.
• Insiders have been net sellers, disposing of 134,471 shares worth $82.2 million over the past three months, while institutional investors and hedge funds own 77.98% of the stock.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) has received a consensus recommendation of "Hold" from the twelve brokerages that are covering the firm, Marketbeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $595.20.

MEDP has been the subject of several recent research reports. TD Cowen upped their price objective on Medpace from $419.00 to $492.00 and gave the stock a "hold" rating in a research report on Friday, July 24th. BMO Capital Markets lifted their target price on Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research report on Friday, July 24th. Barclays set a $600.00 price target on Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada raised their price target on shares of Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Finally, Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and boosted their price objective for the stock from $490.00 to $515.00 in a research report on Tuesday, July 7th.

Insider Buying and Selling at Medpace

In other Medpace news, CEO August Troendle sold 27,174 shares of Medpace stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $618.79, for a total value of $16,814,999.46. Following the sale, the chief executive officer directly owned 561,195 shares in the company, valued at approximately $347,261,854.05. The trade was a 4.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Fred Davenport, Jr. sold 7,283 shares of the business's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the sale, the director directly owned 3,798 shares in the company, valued at $2,302,157.70. This trade represents a 65.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 134,471 shares of company stock worth $82,151,311 in the last three months. 20.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MEDP. Corient Private Wealth LP grew its stake in Medpace by 291.4% in the second quarter. Corient Private Wealth LP now owns 6,314 shares of the company's stock valued at $3,344,000 after purchasing an additional 4,701 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Medpace during the 2nd quarter worth approximately $5,460,000. California State Teachers Retirement System raised its stake in shares of Medpace by 53,619.6% during the 2nd quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company's stock worth $7,408,778,000 after purchasing an additional 13,963,607 shares in the last quarter. HB Wealth Management LLC boosted its holdings in shares of Medpace by 3.9% in the 2nd quarter. HB Wealth Management LLC now owns 1,858 shares of the company's stock valued at $984,000 after buying an additional 69 shares during the last quarter. Finally, AlphaGrep UK Ltd acquired a new stake in shares of Medpace in the 2nd quarter valued at approximately $466,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Up 0.1%

Shares of NASDAQ:MEDP opened at $593.39 on Friday. The firm has a market cap of $16.56 billion, a price-to-earnings ratio of 34.78, a PEG ratio of 2.65 and a beta of 1.15. Medpace has a 12 month low of $373.00 and a 12 month high of $677.90. The company's fifty day simple moving average is $573.38 and its 200 day simple moving average is $498.87.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same period in the prior year, the business earned $3.10 EPS. The company's revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts expect that Medpace will post 17.54 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source